United States· US:59148-245_30e40a02-9942-4914-8d84-cf5a8058cec6
ABILIFY MAINTENA
A medicinal product, registered in United States by Otsuka America Pharmaceutical, Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Manufacturer
- Otsuka America Pharmaceutical, Inc.
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1159148-245-12
- ndc1159148245121 KIT in 1 CARTON (59148-245-12) * 1.9 mL in 1 VIAL, SINGLE-USE (59148-238-90) * 2.5 mL in 1 VIAL, SINGLE-USE (59148-100-12)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b1de9653-ed80-413d-9641-f13d1b7312dc GET /v1/drugs/b1de9653-ed80-413d-9641-f13d1b7312dc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": null,
"source": "ndc",
"strength": null,
"substance": null,
"productndc": "59148-245",
"dosage_form": "KIT",
"dea_schedule": null,
"strength_unit": null,
"application_number": "NDA202971",
"marketing_category": "NDA"
}See everything about ABILIFY.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.